From innovation to action: MSF shares 25 years of lessons learned in tackling Drug-Resistant TB
January 22, 2025January 22, 2025, New Delhi: Médecins Sans Frontières (MSF)/Doctors Without Borders, in partnership with the National TB Elimination Program (NTEP) and the Brihanmumbai Municipal Corporation (BMC), hosted a panel discussion today to mark the culmination of 25 years of continuous...
Read more
MSF calls for equitable access to TB drugs and diagnostics in first-ever plenary session on access at the TB Union Conference
November 13, 2024Bali/Geneva, 13 November 2024 – At the premier global conference on tuberculosis (TB), the annual Union World Conference on Lung Health, taking place in Bali, Indonesia, Christophe Perrin, TB Advocacy Pharmacist at MSF’s Access Campaign, was invited to present on...
Read more
After 18 years, MSF hands over its Drug-Resistant Tuberculosis (DR-TB) Project to the National TB Elimination Program in Mumbai
September 27, 202427 Sept 2024, Mumbai: Médecins Sans Frontières (MSF)/Doctors Without Borders today announced the planned closure of its Mumbai-based Drug-Resistant Tuberculosis (DR-TB) project by the end of 2024. This significant initiative has been providing comprehensive care to patients with complex cases...
Read more
Médecins Sans Frontières Wraps Up Tuberculosis Project in Dushanbe, Tajikistan: A Timeline of Achievements
June 19, 2024Dushanbe, Tajikistan – As Médecins Sans Frontières (MSF) concludes its tuberculosis (TB) project in Dushanbe, Tajikistan, after 13 years of collaboration with the Ministry of Health and Social Protection of Population, we reflect on the programme's journey.MSF’s work in Dushanbe...
Read more
India: Mumbai TB Symposium Focuses on Advancing TB Treatment and Collaboration
June 11, 202410 June 2024, Mumbai: A pivotal symposium organised today by Médecins Sans Frontières (MSF)/Doctors Without Borders brought together a diverse coalition of experts and stakeholders to forge actionable strategies against Drug-Resistant Tuberculosis (DRTB). This crucial gathering aimed to highlight the...
Read more
MSF reveals cost of its landmark TB clinical trial: €34 million
April 26, 2024MSF urges public and non-profit actors to publish clinical trial costs to improve access to medical products for all. Geneva, 25 April 2024 - At the 5th WHO Pharmaceutical Pricing and Reimbursement Policies conference today, Doctors Without Borders/Médecins Sans Frontières...
Read more
Myanmar: I have defeated TB and I wish the same for other patients
April 8, 2024Multi-drug resistant tuberculosis is one of the most complex types of tuberculosis you can get. As opposed to drug-sensitive, which responds well to the medication, multi-drug resistant tuberculosis, by its very name, is resistant to some of the drugs used...
Read more
Patient Stories: Ensuring recovery through timely, accurate drug-resistant tuberculosis testing
March 18, 2024Ahmad, 11, from Tatlay Aali, a town in Gujranwala district, Pakistan, was diagnosed with tuberculosis (TB) when he was just five years old. "We’d never heard about this disease, nobody from our family ever had it. At the same time,...
Read more
MSF: TB test price reduction by Cepheid and Danaher is an important step in the right direction
September 19, 2023Cepheid and its parent company Danaher announced today that they are reducing the price of the Xpert MTB/RIF test for TB by 20 percent in high-TB-burden countries from US$9.98 to $7.97 per test. This reduction is a significant step, considering the...
Read more
Ahead of UN TB High-Level Meeting, US corporations J&J and Cepheid must pledge access to lifesaving TB medicines and tests for everyone in need
September 12, 2023TB is curable but remains the world’s leading infectious disease killer 12 September 2023, Geneva/New York – Next week, world leaders meet for the second-ever global tuberculosis (TB) High-Level Meeting at the United Nations (UN) in New York, to endorse...
Read more
MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics
July 18, 2023MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics. Recent deal offering controlled generics access in limited countries does not go...
Read more
MSF applauds Indian Patent Office’s rejection of Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug
March 23, 2023Mumbai, 23 March 2023 – Today, the 2019 patent challenge by two tuberculosis (TB) survivors, Nandita Venkatesan and Phumeza Tisile, was successful: the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly...
Read more
